On April 9, 2026 Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin (A1AT) deficiency, reported its participation in the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This event is being held in a virtual format during which Company management will deliver a presentation and participate in one-on-one meetings with investors. Dr. Clarissa Desjardins, Chief Executive Officer of Congruence, will present on Monday, April 13, 2026, at 9:30 am ET.

(Press release, Congruence Therapeutics, APR 9, 2026, View Source [SID1234664265])